Health economics: the start of clinical freedom
暂无分享,去创建一个
Tatiana Dilla | José Antonio Sacristán | M. Costi | T. Dilla | J. Sacristán | A. Valladares | María Costi | Amparo Valladares
[1] David O Meltzer,et al. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes. , 2006, Diabetes care.
[2] L. Prosser,et al. Cost-Effectiveness of Cholesterol-Lowering Therapies according to Selected Patient Characteristics , 2000, Annals of Internal Medicine.
[3] A. Maynard. Evidence-based medicine: an incomplete method for informing treatment choices , 1997, The Lancet.
[4] Y. Moride,et al. Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. , 2007, Clinical therapeutics.
[5] J. Hampton,et al. The end of clinical freedom. , 1983, Rivista dell'infermiere.
[6] T G Ganiats,et al. Incremental cost-effectiveness analysis: the optimal strategy depends on the strategy set. , 1999, Journal of clinical epidemiology.
[7] J. Lunshof. Personalized medicine: how much can we afford? A bioethics perspective. , 2005, Personalized medicine.
[8] D. Churchill,et al. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[9] A. Maynard. DEVELOPING THE HEALTH CARE MARKET , 1991 .